Fibroadenoma

Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Ovarian cancer, Enzyme, DNA repair, Abbott Laboratories, Survival, Disease, Patient, Committee, Knowledge, DNA, Cancer, Female, Regulation, Laboratory, EMA, IRIS, Ludwigshafen, Woman, PARP, European, COMP, Sponsor, European Commission, Fibroadenoma, Safety, Marketing, Medicine, Pharmaceutical industry

Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Key Points: 


Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Other Health, Other Science, General Health, Research, Science, GOT2, Patient, TIGAR, AACR, Transgene, PPF (company), PARP, Fibroadenoma, Glycolysis, Pharmaceutical industry

SOTIO Biotech , a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California.

Key Points: 
  • SOTIO Biotech , a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California.
  • In a poster at the conference, SOTIO will present data from the company’s BOXR platform of enhanced T cell therapies.
  • Compared to unmodified CAR T cells and CAR T cells enhanced with GOT2 solely, CAR T cells enhanced with GOT2 and TIGAR showed better tumor infiltration, lower levels of exhaustion, and superior anti-tumor activity in a mouse model of solid tumors.
  • SOTIO’s lead candidate from the BOXR platform, BOXR1030 — a GOT2-enhanced CAR T-cell therapy — is currently being evaluated in a Phase 1/2 study for patients with solid tumors.

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Retrieved on: 
Saturday, March 16, 2024
Diagnosis, Ovarian cancer, MIRV, Mutation, Health, BRCA, Science, Disease, Partnership, Patient, Education, Glomus tumor, Roche, Biomarker, Neoplasm, Research, Cancer, EOC, Recombinant DNA, Woman, HRP, PARP, TTD, Fibroadenoma, HRD, Mirvetuximab soravtansine, BRCA2, Recurrence, LH, BRCA1, ADP, Pharmaceutical industry

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

Key Points: 
  • The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
  • Labcorp researchers conducted two studies to generate further evidence of the value of comprehensive genomic profiling to drive guideline-compliant testing that enables increased patient access to targeted therapies for improved outcomes.
  • When combined, the results of BRCA and HRD testing can determine which patients are most likely to benefit from treatment with poly-ADP ribose polymerase (PARP) inhibitors.
  • "This research emphasizes the power of comprehensive biomarker testing in advancing the treatment of ovarian cancer.

 Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Retrieved on: 
Thursday, March 7, 2024
Research, Women, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Oncology, Cancer, Woman, Omics, Uterine serous carcinoma, Female, EOC, Risk, Safety, Biomarker, Prognosis, Endometrial cancer, DDR, USC, Patient, Fibroadenoma, Infection, Diagnosis, WEE1, Lymph, Fallopian tube cancer

The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.

Key Points: 
  • The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.
  • Two out of the three expansion arms of the study will be using biomarkers to pre-select patients with different solid tumors while the third arm will be treating patients with recurrent serous endometrial carcinoma.
  • Maximizing efficacy, while preserving safety are key elements that Debiopharm is eager to assess throughout the clinical development of Debio 0123.
  • With the successful realization of these requirements, Debio 0123 could become the first choice WEE1 inhibitor.

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

Retrieved on: 
Tuesday, January 23, 2024
Woman, Ovarian cancer, Research, Fibroadenoma, JPO, Cancer, Vaccination, National Cancer Institute, Vaccine, Patent, Pharmaceutical industry

SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application titled "Ovarian Cancer Vaccines."

Key Points: 
  • Anixa Chairman and CEO Dr. Amit Kumar commented, "This new Japanese patent extends the expanded claims for this novel ovarian cancer vaccine technology to another geographic region, joining the European and U.S. patents awarded last year.
  • The Ovarian Cancer Vaccines patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic.
  • The results indicate that vaccinating women against AMHR2-ED could provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer.
  • Anixa is the exclusive worldwide licensee for the vaccine technology from Cleveland Clinic, a nonprofit, multispecialty academic medical center.

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results

Retrieved on: 
Wednesday, January 10, 2024
Distributor, Hope, Woman, Neoplasm, Patient, Endometriosis, Kidney, Neurology, Breast cancer, Malignancy, Freezing, Society, Classification, De novo, Food, Fibroadenoma, Medication, Liver, FDA, CME, Cryoablation, ICE3, Letter, Physician, Human, Lung, Annual general meeting, Kidney cancer, Cryotherapy, Growth, Pharmaceutical industry

Increased Revenues, System, and Probe Sales: Based on our expected preliminary unaudited 2023 results, ProSense® system and disposable probe sales increased by 26% globally over 2022.

Key Points: 
  • Increased Revenues, System, and Probe Sales: Based on our expected preliminary unaudited 2023 results, ProSense® system and disposable probe sales increased by 26% globally over 2022.
  • On a preliminary unaudited basis, as of December 31, 2023, we had cash and cash equivalents, including short-term deposits, of $11 million.
  • The above information reflects preliminary unaudited estimates with respect to certain results of IceCure for the full year ended December 31, 2023, based on currently available information.
  • Because the audit for 2023 is not yet complete, the Company's final results may vary from the preliminary estimates provided herein.

Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)

Retrieved on: 
Thursday, September 28, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibroadenoma, European Society of Gynaecological Oncology, DLT, Congress Center, ESGO, University Clinical Centre in Gdańsk, Congress, Patient, Becquerel, Cytoreductive surgery, Istanbul Congress Center, Ovarian cancer, Safety, Pharmaceutical industry

"Oncoinvent is proud to present safety data from our lead candidate, Radspherin® at a major congress of the global gynecological cancer community.

Key Points: 
  • "Oncoinvent is proud to present safety data from our lead candidate, Radspherin® at a major congress of the global gynecological cancer community.
  • We believe this is an important first step as we advance the development of Radspherin® as a new treatment for patients with advanced ovarian cancer,” says CEO Anders Månsson.
  • The safety interim analysis after completion of the dose-limiting toxicity (DLT) period demonstrated that Radspherin® was well tolerated.
  • The highest dose of 7 MBq was recommended following the completion of dose escalation of 1-2-4-7 MBq, as no DLT was observed.

5 Pew-Stewart Scholars Selected to Advance Cutting-Edge Cancer Research

Retrieved on: 
Tuesday, June 13, 2023
The Pew Charitable Trusts, Pew, Cancer, Research, Alexander, Protein, Patient, Diagnosis, Leukemia, Fibroadenoma, Pharmaceutical industry, Birth control

This class marks the 10th year the Alexander and Margaret Stewart Trust has partnered with Pew to build a legacy of innovative cancer research.

Key Points: 
  • This class marks the 10th year the Alexander and Margaret Stewart Trust has partnered with Pew to build a legacy of innovative cancer research.
  • "Cancer is one of the most pressing challenges facing biomedical researchers today," said Susan K. Urahn, Pew's president and CEO.
  • Members of the 2023 class will explore critical issues in cancer research, including studying the development of pediatric cancers, discovering new avenues for treating epithelial ovarian cancer, and pioneering chemistry to make cancer therapies more exact and effective.
  • The 2023 Pew-Stewart Scholars for Cancer Research are:
    Dr. Bar-Peled will improve how proteins are targeted in treating epithelial ovarian cancer.

SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal

Retrieved on: 
Tuesday, March 7, 2023
MSD, Toxicity, PD-1, Merck, Doctor of Science, Antibody, Immunotherapy, Cancer, SLS, Nivolumab, Immunoglobulin G, WT1, Recurrence, Clinical trial, Peptide, Fibroadenoma, GPS, Maintenance, Collection, Survival, Treatment, Progression-free survival, MD, Merck & Co., A Few More Published Studies, Pharmaceutical industry, Vaccine, Patient, Ovarian cancer

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”) today announced that the previously reported results from the final analysis of a Phase 1 clinical trial of the combination of galinpepimut-S (GPS) with the anti-PD-1 antibody nivolumab (Opdivo®) in patients with relapsed WT1-expressing ovarian cancers (NCT02737787) have been published in the peer-reviewed journal Cancers.

Key Points: 
  • “A significant unmet medical need exists for patients with advanced epithelial ovarian cancer following initial surgery and chemotherapy, with over 70% experiencing recurrence after they achieve clinical remission,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
  • Key Takeaways of Published Study Data:
    Broader than expected GPS immunologic responses encompassed both T-cells and antibodies.
  • Data suggest that durable responses to maintenance GPS immunotherapy can be attained in patients with WT1-expressing ovarian cancer, thus delaying measurable disease relapse.
  • This study was conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Rahway, N.J., USA (known as MSD outside the United States and Canada).

Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

Retrieved on: 
Tuesday, November 15, 2022
Organic, Food and Drug Administration, Folate receptor 1, Benchmark, Health, Society, FOLR1, Dow Jones, Ovarian cancer, ROG, Paclitaxel, RO, Woman, IHC, Hoffmann-La Roche, Fallopian tube, Research, Gynaecology, Genentech, Biomarker, FDA, Immunohistochemistry, Carboplatin, Dick's Picks Volume 32, ADC, Accelerated approval (FDA), Patient, Fibroadenoma, Veni, vidi, vici, Pharma, Roche Diagnostics, International Agency for Research on Cancer, ImmunoGen, US Foods, Analytic, Food, Disease, EOC, Clear-cell ovarian carcinoma, Medical imaging, Pharmaceutical industry, Fine chemical, Chugai Pharmaceutical Co., Cojocaru, Diagnosis, Cancer

The new test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.

Key Points: 
  • The new test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.
  • ELAHERE is a first-in-class antibody-drug conjugate (ADC) therapy developed by ImmunoGen, Inc., approved under FDA's Accelerated Approval program for the treatment of FR-positive platinum-resistant ovarian cancer.
  • "We're proud to expand our women's health and oncology portfolios through the addition of the first companion diagnostic IHC test for ovarian cancer," said Jill German, Head of Pathology Lab at Roche Diagnostics.
  • "This test will enable clinicians to make more informed treatment decisions for patients with ovarian cancer by quickly determining whether they qualify for ELAHERE therapy, potentially improving their outcomes."